Zhai Yusen, Fan Mengchen, Geng Baocheng, Du Xue, Snyder Scott, Wilkinson Larrell
Department of Human Studies, The University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Computer Science, The University of Alabama at Birmingham, Birmingham, AL, USA.
Lancet Reg Health Am. 2024 Aug 9;37:100852. doi: 10.1016/j.lana.2024.100852. eCollection 2024 Sep.
Existing research lacks information on the potential impacts of multi-phased coronavirus disease 2019 (COVID-19) vaccine rollouts on population mental health. This study aims to evaluate the impact of various COVID-19 vaccine rollout phases on trends and prevalence of anxiety and depression among US adults at a population level.
We performed a US population-based multi-intervention interrupted time series analysis through Deep Learning and autoregressive integrated moving average (ARIMA) approaches, analyzing 4 waves of US CDC's Behavioral Risk Factor Surveillance System (BRFSS) data (January 2019-February 2023) to assess changes in the weekly prevalence of anxiety and depression following interruptions, including all major COVID-19 vaccine rollout phases from 2020 to early 2023 while considering pandemic-related events.
Among 1,615,643 US adults (1,011,300 [76.4%] aged 18-64 years, 867,826 [51.2%] female, 126,594 [16.9%] Hispanic, 120,380 [11.9%] non-Hispanic Black, 1,191,668 [61.7%] non-Hispanic White, and 113,461 [9.5%] other non-Hispanic people of color), we found that three COVID-19 vaccine rollout phases (ie, prioritization for educational/childcare workers, boosters for all US adults, authorization for young children) were associated with a 0.93 percentage-point (95% CI -1.81 to -0.04, p = 0.041), 1.28 percentage-point (95% CI -2.32 to -0.24, p = 0.017), and 0.89 percentage-point (95% CI -1.56 to -0.22, p = 0.010) reduction, respectively, in anxiety and depression prevalence among the general US adult population despite an upward trend in the prevalence of anxiety and depression from 2019 to early 2023. Among different population groups, Phase 1 was associated with increases in anxiety and depression prevalence among Black/African Americans (2.26 percentage-point, 95% CI 0.24-4.28, p = 0.029), other non-Hispanic people of color (2.68 percentage-point, 95% CI 0.36-5.00, p = 0.024), and lower-income individuals (3.95 percentage-point, 95% CI 2.20-5.71, p < 0.0001).
Our findings suggest disparate effects of phased COVID-19 vaccine rollout on mental health across US populations, underlining the need for careful planning in future strategies for phased disease prevention and interventions.
None.
现有研究缺乏关于2019冠状病毒病（COVID-19）多阶段疫苗接种对人群心理健康潜在影响的信息。本研究旨在评估不同阶段的COVID-19疫苗接种对美国成年人焦虑和抑郁趋势及患病率的影响。
我们通过深度学习和自回归积分滑动平均（ARIMA）方法进行了一项基于美国人群的多干预中断时间序列分析，分析了美国疾病控制与预防中心行为风险因素监测系统（BRFSS）的4波数据（2019年1月至2023年2月），以评估中断后焦虑和抑郁每周患病率的变化，包括2020年至2023年初所有主要的COVID-19疫苗接种阶段，同时考虑与疫情相关的事件。
在1,615,643名美国成年人中（1,011,300名[76.4%]年龄在18 - 64岁之间，867,826名[51.2%]为女性，126,594名[16.9%]为西班牙裔，120,380名[11.9%]为非西班牙裔黑人，1,191,668名[61.7%]为非西班牙裔白人，113,461名[9.5%]为其他非西班牙裔有色人种），我们发现三个COVID-19疫苗接种阶段（即教育/儿童保育工作者优先接种、所有美国成年人接种加强针、幼儿接种获批）分别与美国普通成年人群焦虑和抑郁患病率降低0.93个百分点（95%置信区间 -1.81至 -0.04，p = 0.041）、1.28个百分点（95%置信区间 -2.32至 -0.24，p = 0.017）和0.89个百分点（95%置信区间 -1.56至 -0.22，p = 0.010）相关，尽管2019年至2023年初焦虑和抑郁患病率呈上升趋势。在不同人群组中，第一阶段与黑人/非裔美国人（2.26个百分点，95%置信区间0.24 - 4.28，p = 0.029）、其他非西班牙裔有色人种（2.68个百分点，95%置信区间0.36 - 5.00，p = 0.024）和低收入个体（3.95个百分点，95%置信区间2.20 - 5.71，p < 0.0001）的焦虑和抑郁患病率增加相关。
我们的研究结果表明，分阶段的COVID-19疫苗接种对美国不同人群的心理健康有不同影响，强调在未来分阶段疾病预防和干预策略中进行仔细规划的必要性。
无。
